- Registered in Europe and complies with all EU requirements
- Passed safety study in Europe5
- Polyoxidonium® studies are conducted in accordance with high international standards
For prevention and treatment of viral infections
activate body's immune response to viruses1
increase body's resistance to infections of any etiology1
decrease disease duration and severity2,4
Polyoxidonium® is approved by MH RF or performance of III phase international multicenter placebo-controlled clinical study (IMCS) of efficacy in the treatment of COVID-19 coronavirus infection.
Polyoxidonium® is included into Slovak clinical recommendations on COVID-19 treatment.
Polyoxidonium® is included into methodical recommendations on ARVI and flu treatment during the COVID-19 epidemy.
Polyoxidonium® is included into guidelines and supported by leading scientific organizations
For respiratory viral infections prevention:
- children aged 3 years and older
½ of a tablet 1 time a day for 7 days - children aged 10 years and older
1 tablet 1 time a day for 7 days - adults
1 tablet 1 time a day for 10 days
For respiratory viral infections treatment1:
- children aged 3 years and older
½ of a tablet 2 times a day for 7 days - children aged 10 years and older
1 tablet 2 times a day for 7 days - adults
1 tablet 2 times a day for 7 days
Polyoxidonium® to combat respiratory viral infections
Polyoxidonium® can have a combined effect on the course of respiratory viral infections1:
- can decrease disease severity3,
- decreases inflammation4,
- boosts immunity and reduces the number of repeated cases of ARVI6.
In case of any drug-associated adverse events or any claims to the product quality, please contact NPO Petrovax Pharm, LLC:
by e-mail: ADR@petrovax.ru
Or use pharmacovigilance feedback page: http://petrovax.ru/medication/safety
Footnotes
- Patient information leaflet for Polyoxidonium®.
- Malanicheva, T.G., Agafonova, E.V. (2018). The effectiveness of immunomodulatory therapy of community-acquired pneumonia in frequently ill children. Children Infections, 17(4), 38–43.
- Garaschenko, T.I., Karneeva, O.V., Tarasova, G.D., et al. (2020). Influence of local application of Polyoxidonium® on symptoms and course of acute respiratory viral infection in children: results of multicenter double-blind placebo-controlled study. Consilium Medicum, 22(3), 80–86.
- Karaulov, A.V., Gorelov, A.V. (2019). The use of azoximer bromide for treatment of inflammatory infections of respiratory system in children: a meta-analysis of controlled clinical studies. Journal of Infectology, vol. 11, No. 4, 31–41.
- Pruzinec, P., Chirun, N., Sveikata, A. (2018). The safety profile of Polyoxidonium® in daily practice: results from postmarketing safety study in Slovakia. Immunotherapy, 10(2), 1–7.
- Kharit, S.M., Galustyan, A.N. (2017). Azoximer bromide is a safe and effective drug for treatment of acute upper respiratory tract infections in children: an overview of the results of double-blind, placebo-controlled, randomized clinical trials of phase II and III. Pediatrics (Appendix to Consilium Medicum), 2.